Client News

[at noodls] - NEW YORK and HERZLIYA PITUACH, Israel, Nov. 26, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NasdaqCM: IMNP; "Immune" or "the Company"), a clinical stage biopharmaceutical company ...
Posted: November 26, 2014, 11:07 pm
Posted: November 26, 2014, 11:02 pm
Posted: November 26, 2014, 11:02 pm
[PR Newswire] - NEW YORK, Nov. 26, 2014 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alcobra Ltd. ("Alcobra" or the "Company") (NASDAQ: ADHD) of ...
Posted: November 26, 2014, 9:44 pm
[PR Newswire] - "Immune" or "the Company"), a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million. The Company received aggregate net proceeds of approximately $8.645 million, after deducting underwriting discounts and commissions and estimated offering expenses. In total, the Company issued 3,909,697 units, with each unit consisting of one share of the Company's common stock, par value $0.0001 per share, and one warrant to purchase 0.25 of a share of the Company's common stock, at an exercise price of $3.75 per a whole share.
Posted: November 26, 2014, 9:15 pm
[AP] - A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: Ohr Pharmaceutical fell 32.1 percent to $7.74. Web.com Inc. fell 19.9 percent to $27.70. Aemetis Inc. fell 12.5 percent ...
Posted: November 26, 2014, 7:03 pm
Posted: November 26, 2014, 6:04 pm
[at noodls] - Timothy Henry, MD, of Cedars-Sinai Heart Institute, to Review Clinical Data from Phase 2 PreSERVE AMI Trial New York Nov. 26, 2014 - NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel ...
Posted: November 26, 2014, 1:47 pm
[GlobeNewswire] - NEW YORK -- NeoStem, Inc. , a biopharmaceutical company developing novel cell based therapeutics, announced today that it will host a Key Opinion Leader event webcast on Monday, December 1, 2014 from 4:30 ...
Posted: November 26, 2014, 12:30 pm
[PR Newswire] - "Immune" or "the Company"), a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced the closing of its previously announced underwritten public offering of 3,450,000 units, with each unit consisting of one share of the Company's common stock, par value $0.0001 per share, and one warrant to purchase 0.25 of a share of the Company's common stock, at a price to the public of $2.50 per unit. The warrants will be exercisable for a period of three years following the issuance thereof at an exercise price of $3.75 per a whole share. In connection with the offering, the Company has also granted the underwriter a 30-day option to purchase up to an additional 517,500 units offered in the public offering to cover over-allotments, if any.
Posted: November 25, 2014, 9:15 pm
[Business Wire] - Cynapsus Therapeutics Inc. , a specialty pharmaceutical company focused on Parkinson’s disease, today announced that its common shares will commence trading on the Toronto Stock Exchange as of the opening of trading on Friday, November 28, 2014.
Posted: November 25, 2014, 9:10 pm
[GlobeNewswire] - NEW YORK -- The Rosen Law Firm announces that a class action lawsuit has been filed on behalf of purchasers of Alcobra Ltd. common stock during the period from March 28, 2014 through November 14, 2014. ...
Posted: November 25, 2014, 8:11 pm
[at noodls] - BOTHELL, WA - November 25, 2014 - BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ...
Posted: November 25, 2014, 7:53 pm
[at noodls] - WIXOM, Mich., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) ...
Posted: November 25, 2014, 6:39 pm
[GlobeNewswire] - WIXOM, Mich. -- Rockwell Medical, Inc. , a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for ...
Posted: November 25, 2014, 6:26 pm
Posted: November 25, 2014, 6:04 pm
Posted: November 25, 2014, 6:04 pm
[at noodls] - Robert A. Preti, Ph.D. to take on new role at industry advocacy organization effective January 1, 2015 New York, November 25, 2014 - NeoStem, Inc. (Nasdaq:NBS) announced today that Dr. Robert Preti, the ...
Posted: November 25, 2014, 1:57 pm